Swk Hldgs Corp Stock Price, News & Analysis

SWK Holdings Corporation (Nasdaq: SWKH) will participate in Maxim's 2022 Virtual Growth Conference from March 28-30, 2022. Chairman and CEO Winston Black will present a pre-recorded overview of the company's business strategy and recent achievements. The presentation will be accessible on-demand for registered attendees, and the management team will hold virtual one-on-one meetings. SWK specializes in financing for small- and mid-sized companies in the healthcare sector, partnering with product marketers and royalty holders to deliver flexible financial solutions.

Enteris BioPharma, a subsidiary of SWK Holdings (Nasdaq: SWKH), has published a white paper titled "HPAPI Drug Solid Oral Dosage Manufacturing – Ensuring Content Uniformity." The paper discusses challenges in ensuring content uniformity with high potency active pharmaceutical ingredients (HPAPIs) and highlights the advantages of dry production techniques. Enteris recently renovated its manufacturing plant in Boonton, NJ, now featuring a state-of-the-art facility dedicated to HPAPI manufacturing. The HPAPI market is projected to exceed $32 billion by 2026, presenting substantial growth opportunities.

Enteris BioPharma, a subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), will participate in DCAT Week 2022 from March 21-24, 2022, in New York City. The management team will engage with pharmaceutical executives to promote its Contract Manufacturing Organization (CMO) services for solid oral doses, especially for challenging compounds like peptides and highly potent small molecules. Enteris offers comprehensive clinical trial materials manufacturing from Phase 1 to Phase 3 and has a state-of-the-art facility for high potency active pharmaceutical ingredients.

SWK Holdings Corporation (SWKH), a specialty finance firm focused on life sciences, has restructured its Board of Directors as of February 15, 2022. New independent directors Wendy DiCicco and Robert K. Hatcher join Laurie Dotter, who was appointed earlier in February. This board reconstitution aims to leverage the extensive financial and operational expertise of the new members to drive growth and enhance the company's strategic initiatives. CEO Winston Black emphasized the importance of these appointments in navigating market dynamics to improve financial offerings.

Enteris BioPharma, a subsidiary of SWK Holdings (Nasdaq: SWKH), announced progress on its oral feasibility programs utilizing its Peptelligence® and ProPerma® technologies. In 2021, Enteris initiated six programs targeting various therapeutic areas, including cancer and CNS disorders. The Peptelligence platform enhances oral delivery of peptide drugs, while ProPerma improves solubility for small molecules. Enteris has received $28 million from Cara Therapeutics, with potential future milestones linked to their oral formulation, Oral KORSUVA. These advancements showcase Enteris' capacity to transform drug delivery.

SWK Holdings Corporation (Nasdaq: SWKH) updated its portfolio performance for the second half of 2021, highlighting new financings including $10 million to MolecuLight and $12 million to Biotricity (NASDAQ: BTCY). CEO Winston Black noted that 2022 aims to restore deal origination to historical levels. Enteris BioPharma's partnership with Cara Therapeutics is advancing with a $5 million milestone payment. Additionally, Biolase (NASDAQ: BVS) anticipates a 44-47% revenue increase for the fourth quarter. SWK focuses on providing flexible financing solutions to small and mid-sized life science companies.

Enteris BioPharma, a subsidiary of SWK Holdings (Nasdaq: SWKH), has launched a redesigned corporate website showcasing its comprehensive Bench to Market™ services. The website provides pharmaceutical customers with a detailed overview of Enteris' core technologies, including its Peptelligence® and ProPerma® oral drug delivery platforms. This upgrade aims to facilitate partnerships by offering clear insights into Enteris' capabilities in contract development and manufacturing. CEO Rajiv Khosla emphasized the expansion of Enteris' services, catering to pharmaceutical companies needing development and manufacturing support for oral drug products.

SWK Holdings Corporation (Nasdaq: SWKH) announced that its Special Committee has concluded its investigation regarding Carlson Capital's non-binding proposal to acquire remaining shares at $20.20 each. Following discussions and counterproposals, the Special Committee determined an agreement could not be reached and decided to dissolve. The Company remains focused on growing its specialty finance business within the global healthcare sector, as previously stated on November 1, 2021.

Enteris BioPharma, a subsidiary of SWK Holdings (Nasdaq: SWKH), showcased its 2021 achievements and 2022 growth potential in its latest press release. Key highlights include the expansion of its manufacturing capabilities in Boonton, NJ, enhancing its contract development and manufacturing organization (CDMO) services. Enteris successfully completed a Phase 1 trial for its Peptelligence oral tablet formulation of leuprolide and secured $15 million in milestone payments from Cara Therapeutics for the development of Oral KORSUVA. The company anticipates significant growth opportunities through new partnerships and internal development programs in the upcoming year.